Hyperthermia, with no signs of any underlying infection, may occur in the course of neuroleptic malignant syndrome, fatal catatonia, heat stroke, or malignant hyperthermia. We describe hyperthermia as a complication after discontinuance of antiparkinsonian treatment with levodopa/carbidopa and bromocriptine. Impaired nigrostriatal, hypothalamic, and mesolimbic dopaminergic functions could be involved in pathogenesis.
We present 8 cases of centrally-originating hyperthermic syndrome, the initial cause being either neuroleptic malingnant syndrome, hyperthemia after discontinuance of antiparkinsonian therapy or heatstroke. We review the physiological and neurochemical mechanisms involved in thermoregulation, emphasizing the role of dopamine. A single mechanism, consistent with pharmacological or neuropathological impairment of the dopaminergic system, could be responsible for all the cases of hyperthermic syndrome presented.
BACKGROUND: Despite recent advances multiple myeloma remains an incurable plasma cell malignancy. Thalidomide has recently been recognized as an effective agent for previously untreated, refractory or relapsed myeloma. DESIGN AND METHODS: Thirty patients with refractory/relapsed MM (22 females, 8 males) aged from 53 to 81yrs : 18 MM IgG(k), 3 MM IgA(k), 6 MM IgG(l), 2 MM IgA(l) an MM (l) were treated with thalidomide in combination with high doses (40 mg monthly) of dexamethasone and monthly zolendronate( 4 mg).All patients were treated with conventional escalated dose of thalidomide every 2 weeks starting from 100 mg daily to max tolerated dose. Of the 30 patients 19 (63 %) responded to therapy with a monoclonal reduction of more than 50% ( 4 acheived CR). Among the responders those with polineurophaty documented as a subjective simptom and with electrophysiologic objective parameters alteration entered in a reduced thalidomide schedule of 100 mg daily 10 days a month. The follow up of these patients actually ranges between 2 to 21 months, 1 patient progressed and 2 patients discontinued treatment because of a subjective progression of neurological simptoms but without electrophysiologic alterations. RESULTS: None of the patients treated with intermittent low doses of Thalidomide developped an increase of neurophaty. Intermittent low doses of THAL may be applicable in the maintenance treatment of myeloma patients. Patients status Response Responders Maintenance In Study Progressed Stopped PR 15 (50%) 6 3 1 (4 mo) 2 (3 and 6 mo) CR 4 (13 %) 2 2 0 0
Novel agents for MM treatment such as TAL, bortezomib and lenalidomide while offering higher rates of response and CR have lead to new side-effects, in particular peripheral neuropathy that is dose limiting in more than 40% of patients. We have investigated the toxicity and the effectivness of low doses of TAL as maintenance treatment in MM in order to minimize this harmful side-effect. METHODS: From October 1999, 54 pts (20 males/34 females) with advanced/relapsed MM (IgG-K 28; IgG-λ 11; IgA-K 8; IgA-λ 4; λ 2; K 1) were treated with TAL at 100 mg/day; if well tolerated, the dose could be increased to a maximum of 400 mg/day. 2 pts stopped treatment and weren’t valuables for response. 11 pts (20%) progressed and 5 (9%) reached only a stable disease/minimal response. 27 pts (50%) responded to treatment with 22 (81%) PR (> 50% of reduction of MC) and 5 (9%) CR. Somnolence and stypsis were seen in all pts but were reversible and treated with symptomatic drugs. In 17 pts (11 F, 6 M, median age 70 yrs) we observed a symptomatic neuropathy and we decided to reduce dosage at 100 mg dayly only for 10 days at month as MT. All other causes of neuropathies were excluded. We prospectively performed longitudinal neurological and nerve conduction study before and during TAL treatment every 3 months. Nerve conduction studies included recording of sensory and motor nerve action potential from surale, radial, ulnar, common peroneal and tibial nerves. We considered -p SNAP and Cmap amplitude for each nerve. Electromyography examination was performed in distal muscles of the limbs including denervation potentials and pattern of activation. RESULTS: In 2 out of 17 we found a mild distal sensory-motor neuropathy before TAL treatment. One referred paresthesia in the 8 months before the diagnosis of MM; the other one was asymptomatic and the diagnosis of neuropathy was made on the basis of clinical and electrophysiological data. The 2 pts with PN before TAL treatment showed a mild clinical and electrophysiological progression of the disease after 6 months of therapy. The first clinical symptoms were painful paresthesias and numbness in all pts. At neurological examination we found a symmetric distal polyneuropathy of sensory type with major evidence at lower limbs. Hypopallestesia and hyporeflexia at lower limbs were detected in all pts; in 3 there was areflexia of achillei reflexes. In 2 pts we found hyperesthesia a stock and gloves distribution. No pts showed motor deficits or cranial nerves impairments. In 12 out of 17 pts an axonal sensory-motor neuropathy was found; in 3 pts a pure sensitive neuropathy, more evident at lower limbs, was detected. In the subsequent 58 months follow-up evaluation, no progression of clinical and electrophysiological findings was demonstrated in the 17 pts. Two of them, however, had to discontinue TAL therapy for severe painful paresthesias. After a median of 8 months’ follow-up, 10/17 pts are alive (2–58 months) and in remission (2 CR and 8 PR); 5 pts showed a disease progression after a median therapy of 5 months (2–23 months) and two pts, who had achieved a PR, had to stop therapy because of severe neurotoxicity after 8 months of treatment (5–12 months). CONCLUSIONS: The incidence of TAL neuropathy is high and problematic, but the lower cumulative doses of this schedule appear to be less toxic and manageble also mainteining a high rate of response (58%).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.